JPMorgan Starts Mirati Therapeutics (MRTX) at Underweight
Tweet
Share
E-mailGet Alerts MRTX Hot Sheet
Price: $58.70 --0%
Rating Summary:
8 Buy, 18 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 11 | New: 48
Rating Summary:
8 Buy, 18 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 11 | New: 48
Join SI Premium – FREE
JPMorgan analyst Anupam Rama initiates coverage on Mirati Therapeutics (NASDAQ: MRTX) with a Underweight rating and a price target of $85.00.
For an analyst ratings summary and ratings history on Mirati Therapeutics click here. For more ratings news on Mirati Therapeutics click here.
Shares of Mirati Therapeutics closed at $104.46 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Wedbush Starts Eupraxia Pharmaceuticals (EPRX) at Outperform
- Goldman Sachs Assumes Contineum Therapeutics (CTNM) at Early-Stage Biotech
- Goldman Sachs Assumes Insmed (INSM) at Buy
Create E-mail Alert Related Categories
New CoverageRelated Entities
JPMorganSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
